Knopp NeuroSciences Reports Presentation of Encouraging Clinical Trends in a Phase 2 Study of KNS-760704 in ALS
12/9/2009 9:41:20 AM
BERLIN--(BUSINESS WIRE)--Knopp Neurosciences Inc. (“Knopp”) announced the presentation today of encouraging clinical results in a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (“ALS”). The results were presented at the 20th International Symposium on ALS/MND in Berlin, Germany, by Merit Cudkowicz, M.D., Associate Professor of Neurology at the Massachusetts General Hospital of Harvard Medical School.
comments powered by